Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039520 · ClinicalTrials.gov registry record · Phase 2
Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00039520 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT00039520, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastatic or recurrent breast cancer.
Interventions
- DRUG docetaxel
- DRUG sulindac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2002-01 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00039520
The ClinicalTrials.gov registry entry for NCT00039520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fox Chase Cancer Center, which has 183 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00039520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00039520 about?
NCT00039520 is a clinical study titled "Sulindac and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining sulindac with docetaxel in treating women who have metastat...
What is the current status of trial NCT00039520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2002-01. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00039520?
The interventions under investigation include: docetaxel (DRUG), sulindac (DRUG).
Who is sponsoring clinical trial NCT00039520?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.